Skip to main content

Table 3 Clinical management summary of 13 Ebola virus disease patients treated outside West Africa

From: Ebola virus disease and critical illness

Reference [76] [76] [42] [28, 79, 137] [78, 79, 82] [81, 82] [38] [25, 77] [28, 99] [81] [81] [82] [37]
Demographics
 Gender M F M M M M M F M F F M M
 Age (years) 33 59 36 51 43 42 38 44 33 26 29 44 43
 Country of infection Liberia Liberia Sierra Leone Liberia Sierra Leone Liberia Sierra Leone Spain Liberia USA USA Sierra Leone Sierra Leone
 Country providing care USA USA Germany USA USA USA Germany Spain USA USA USA USA Switzerland
Hospital admission
 Admission date 2 Aug 2014 5 Aug 2014 27 Aug 2014 5 Sep 2014 9 Sep 2014 30 Sep 2014 3 Oct 2014 6 Oct 2014 6 Oct 2014 11 Oct 2014 14 Oct 2014 15 Nov 2014 21 Nov 2014
 Days from diagnosis to evacuation 7 10 4 7 2 N/A 5 0 5 N/A N/A 6 4
 Hospital LOS 19 14 30 20 41 8 47 30 16 13 14 3 15
 Vital status Survived Survived Survived Survived Survived Died Survived Survived Survived Survived Survived Died Survived
Critical care therapies
 Central line N N Y Y Y Y Y N Y Y N Y Y
 Vasopressors N N N N Y Y Y N N N N Y N
 Oxygen Y Y Y Y Y Y Y Y N N N Y N
 NIV (d, days) N N Y (8d) N N N Y (1d) N N N N N N
 MV (d, days) N N N N Y (17d) Y (5d) Y (13d) N N N N Y (3d) N
 CRRT (d, days) N N N N Y (24d) Y (5d) Y (18d) N N N N Y (3d) N
 IHD (d, days) N N N N N N Y (10d) N N N N N N
Experimental therapies
 Convalescent plasma Y N N Y Y N N Y Y Y Y Y N
 ZMapp/ZMab Y Y N N N N N Y N Y N Y Y
 Brincidofovir N N N N N Y N N Y Y Y N N
 Favipiravir N N Y N N N Y Y N N N N Y
TKM N N Y Y Y N N N N Y N N N
 Other N/A N/A N/A N/A N/A N/A Amiodarone, FX06 N/A N/A N/A N/A N/A N/A
  1. CRRT continuous renal replacement therapy; F female, IHD intermittent hemodialysis, LOS length of stay, M male, MV invasive mechanical ventilation, N/A not available, NIV non-invasive ventilation, TKM TKM-Ebola, small interfering ribonucleic acids (siRNA) produced by Tekmira